Morgan Stanley Sees St. Jude Medical as Poised for Acceleration

In a report published Monday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating and $75.00 price target on St. Jude Medical (NYSE: STJ ). In the report, Morgan Stanley noted, “End market stability and pipeline catalysts into 2H14 suggest acceleration across the next several quarters and upside to